Literature DB >> 2837231

SCH 28080 is a lumenally acting, K+-site inhibitor of the gastric (H+ + K+)-ATPase.

D J Keeling1, S M Laing, J Senn-Bilfinger.   

Abstract

SCH 28080 (2-methyl-8-(phenylmethoxy)imidazo[1,2-a] pyridine-3-acetonitrile) is an effective inhibitor of acid secretion in vivo and is a reversible, K+-competitive inhibitor of the gastric (H+ + K+)-ATPase in vitro. The actions of SCH 28080 have been studied on gastric vesicle preparations containing the (H+ + K+)-ATPase. At pH 7, inhibition was competitive with respect to K+ for both ATPase (Ki = 24 nM) and pNPPase (Ki = 275 nM) activities. A close analogue of SCH 28080 (methylated in the 1-N position), that was not expected to cross membranes freely, inhibited ATPase and pNPPase activity less effectively in intact vesicle preparations, where the lumenal (extracellular) face of the membrane was not directly accessible. This suggested that SCH 28080 inhibited both enzyme activities at a lumenal site on the enzyme. Being a protonatable weak base (pKa = 5.6), SCH 28080 would be expected to accumulate on the lumenal, acidic side of the parietal cell membrane in its protonated form. The potency of SCH 28080, relative to that of the "non-protonatable" analogue, increased at low pH, commensurate with the proportion of SCH 28080 in the protonated form. Thus the accumulating protonated form was the active inhibitory species. SCH 28080 (50 nM) blocked the rapid, K+-stimulated dephosphorylation of the catalytic phosphoenzyme intermediate of the (H+ + K+)-ATPase at room temperature. At 4 degrees, higher concentrations of the inhibitor were required, suggesting that the rate of inhibitor binding was slow at low temperatures.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2837231     DOI: 10.1016/0006-2952(88)90586-2

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  7 in total

1.  Effect of Th1 cytokines on acid secretion in pharmacologically characterised mouse gastric glands.

Authors:  I T Padol; R H Hunt
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

Review 2.  Gastric H,K-ATPase as a drug target.

Authors:  Jai Moo Shin; George Sachs
Journal:  Dig Dis Sci       Date:  2006-04-28       Impact factor: 3.199

3.  Cibenzoline, an ATP-sensitive K(+) channel blocker, binds to the K(+)-binding site from the cytoplasmic side of gastric H(+),K(+)-ATPase.

Authors:  Y Tabuchi; H Yashiro; S Hoshina; S Asano; N Takeguchi
Journal:  Br J Pharmacol       Date:  2001-12       Impact factor: 8.739

4.  The basal Mg2(+)-dependent ATPase activity is not part of the (H(+)+K+)-transporting ATPase reaction cycle.

Authors:  H T Van der Hijden; S Kramer-Schmitt; E Grell; J J de Pont
Journal:  Biochem J       Date:  1990-05-01       Impact factor: 3.857

5.  Changes of intracellular pH in rat mesenteric vascular smooth muscle with high-K+ depolarization.

Authors:  C Austin; S Wray
Journal:  J Physiol       Date:  1993-09       Impact factor: 5.182

Review 6.  Role of Acid Suppression in Acid-related Diseases: Proton Pump Inhibitor and Potassium-competitive Acid Blocker.

Authors:  Hideki Mori; Hidekazu Suzuki
Journal:  J Neurogastroenterol Motil       Date:  2019-01-31       Impact factor: 4.924

Review 7.  Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.

Authors:  Kentaro Sugano
Journal:  Therap Adv Gastroenterol       Date:  2018-01-09       Impact factor: 4.409

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.